ZYNE Stock Summary

• The capital turnover (annual revenue relative to shareholder's equity) for ZYNE is 0 -- better than just 7.07% of US stocks.
• With a price/sales ratio of 1,661.62, Zynerba Pharmaceuticals Inc has a higher such ratio than 99.79% of stocks in our set.
• With a year-over-year growth in debt of -41.08%, Zynerba Pharmaceuticals Inc's debt growth rate surpasses merely 7.72% of about US stocks.
• Stocks that are quantitatively similar to ZYNE, based on their financial statements, market capitalization, and price volatility, are BPMX, RVNC, ADVM, PSTI, and PRTA.
• Visit ZYNE's SEC page to see the company's official filings. To visit the company's web site, go to www.zynerba.com.